News

Bioprocess development at Testa Center in Uppsala is now part-funded again: up to five weeks of access per project, with 70 percent of the access fee covered for academic projects and 50 percent for companies. Weeks are allocated first come, first served and must be used by 30 April 2027.

A pre-GMP laboratory in Western Sweden will let ATMP developers prove out their manufacturing processes before committing to a GMP facility. It is one of two resources in Precisionsplattformen, backed by SEK 25 million in EU regional development and Västra Götalandsregionen funding.

The Royal Swedish Academy of Engineering Sciences has set out what Sweden needs to change to hold its position in advanced therapies. The IVA ATMP report asks for three national super-ecosystems, a transferable fast-track voucher at EU level and clearer national guidance on the hospital exemption.

The European Society of Gene and Cell Therapy is looking for its next ECR Board Member. Are you a PhD student or post-doc in gene and cell therapy? Applications close 15 May 2026.

Doctoral Course: From Research to ATMP Treatment

EIB backs Swedish biotech scale-up BioLamina with €20 million to enable stem cell technologies targeting diseases such as type 1 diabetes, Parkinson’s disease, and heart failure

Karolinska Institutet offers a two-week doctoral course designed to provide a comprehensive overview of the entire process involved in developing and producing cell and gene therapy products.

Sweden is strengthening its position in advanced bioanalytics with the launch of the BioAnalytical Cluster of Excellence (BACE), supported by Vinnova.

Want to strengthen your expertise in hospital-based ATMP and cell therapy manufacturing? This three-day course in April 2026 offers practical insight into regulation, quality systems and clinical application.

Mötesplats ATMP i Väst 2026 brings together industry and healthcare experts to enable structured dialogue on advanced therapy medicinal products relevant for Swedish healthcare.

VERIGRAFT has taken an important step in its clinical program by submitting an application for a pivotal Phase II/III clinical trial in Europe, focused on a patient‑specific tissue‑engineered vein therapy for severe venous disease.

What’s the current state of advanced cell & gene therapies in Sweden? Learn more in the latest episode of Rådet från NT-Rådet Podcast.

A new national partnership, Cell & Gene Therapy SWEDEN, is being established to strengthen Sweden’s global competitiveness in advanced therapies through coordinated collaboration between academia, healthcare, and industry.

CCRM Nordic makes its first venture investment, becoming a shareholder in Precision BioAnalytics. The collaboration aims to accelerate ATMP innovation through advanced molecular analysis and infrastructure.

A new EU study reviews how hospital exemptions for ATMPs are applied across member states, highlighting variations, challenges, and opportunities for patients and developers.

Anocca has secured SEK 440 million to advance its VIDAR-1 clinical trial, a pioneering gene-edited TCR-T therapy targeting pancreatic cancer.

A new study published in NEJM shows CRISPR-edited islet cells can function in a person with type 1 diabetes without immunosuppression.

Swedish immunotherapy company CuraCell has received approval to initiate a Phase I/IIa clinical trial of its novel TIL therapy, CC-38.

The Swedish government launches SweTrial, a national partnership to increase clinical trials and strengthen Sweden’s life science competitiveness.

Precision BioAnalytics is a new Swedish biotech company offering high-sensitivity molecular diagnostics for research, infectious disease, and ATMPs.

A new study led by Uppsala University has discovered three genes that control how glioblastoma spreads in the brain, opening doors to better targeted treatments.

On Clinical Trials Day, we celebrate the people and progress behind Swedish ATMP research. Discover active trials and the Hospital ATMP Centers driving change.

Lund University secures €8.3 million from the EU to launch RAMP-UP, a new international PhD programme in regenerative medicine and ATMPs.

A new EU workplan outlines how data and AI will shape the future of medicines regulation, aiming to deliver safer treatments faster across Europe.

CCRM Nordic has signed a strategic MoU with two South Korean organizations at BIO KOREA, promoting global collaboration in ATMP R&D and training.

Swedish patients with aggressive blood cancers are responding well to CAR T-cell therapy, with better survival rates, fewer side effects, and encouraging results even in older adults.

Sweden is launching a national coordination function (Samordningsfunktionen) for ATMP to boost collaboration across sectors and improve patient access to advanced therapies.

The European Medicines Agency (EMA) has launched a Clinical Trial Map, helping patients and healthcare professionals across the EU easily find ongoing clinical trials and improve access to ATMPs.

Unregulated ATMPs are being marketed in the EU, posing serious health risks. Authorities urge patients to verify treatments and seek only approved therapies.

The ATMP Center at Skåne University Hospital in Lund is joining a European initiative to improve the efficiency and sustainability of manufacturing processes for cell and gene therapies.

Cancer remains a major health challenge in Europe, but technological advancements are improving survival rates. While healthcare systems excel in prevention and care, challenges remain in scaling and commercializing innovations.

Gene editing is transforming treatment for hereditary diseases, with new therapies gaining approval. As clinical trials advance, careful risk assessments are crucial to ensure safety and long-term success in genetic disorder treatments.

After Brexit, the EU lost a key advocate for life sciences. To reclaim leadership in pharmaceutical innovation and manufacturing, Europe needs unity and strong alliances, argue industry leaders from Denmark, Finland, and Sweden.

An investment of 16 million SEK aims to further elevate expertise in ATMPs in Western Sweden. The University of Gothenburg is among the key partners in this collaborative effort, bringing together academia, healthcare, and industry.

Sweden leads in ATMP innovation, but pediatric treatments lag behind. Key insights and challenges from the latest ATMP Sweden report.

ATMP2030:s färdplan vill göra Sverige till ett globalt nav för avancerade terapier till 2030. Med fokus på samverkan, kliniska prövningar och hållbarhet ska infrastrukturen stärkas och framtidens behandlingar säkras.

Elicera Therapeutics announced that the first patient has been enrolled in the company's Phase I/II clinical study, CARMA.

Ministers for Energy, Business and Industry, Health Care, Social Affairs, Public Health and Education present their updated life science strategy

Acousort: Towards point of care, closed cell therapy dose preparation

Brought to you by ATMP Sweden – the national network of Sweden’s activities within Advanced Therapy Medicinal Products (ATMPs)

Our colleague, friend and work husband, taken too soon

A booming Swedish ecosystem from research to SME, clinical treatment and employment

Kristina Levan är utsedd till ordförande för den samordningsgrupp och Ewa Ellis som koordinator i projektet

Brought to you by ATMP Sweden – the national network of Sweden’s activities within Advanced Therapy Medicinal Products (ATMPs)

Lots to check out when you are in Gothenburg for ISCT Europe Sept 4-6

Register now for ATMP Sweden 2024! Malmö Nov 25/26

Rekryteringsbehov, efterfrågad kompetens, utbildning och utmaning.

Participation in Clinical Trials, Workforce Diversity and Equitable Recognition of KOLs

Anocca: Sweden’s largest ATMP-developing SME

Milestone celebrated Monday the 13th of May, 2024 at Uppsala Castle

46 Swedish clinical trials reported in ATMP since 2006, 26 since 2021….

The people behind the role, giving us a 'world tour'

Brought to you by ATMP Sweden – the national network of Sweden’s activities within Advanced Therapy Medicinal Products (ATMPs)

Föreningen ATMP Sweden elects a new board

Ny styrgrupp har utsetts att driva jämställd behandling, stötta forskning/translation och stärka samverkan mellan Svensk regioner.

Announces launch of their new advanced therapies analytics company, QVance.

Nordic ATMP stakeholders meet to discuss opportunities in collaboration

Using ‘iTANK’ bacterial transgene to target heterogenous solid tumour environments

Individuals and organizations are now welcomed to register as members.

Mark your calendars and submit your application before the deadline!

Our annual conference in Sweden's oldest and thriving scientific melting pot

Implementation of market-approved ATMPs, clinical trials and hospital-based manufacturing

Brought to you by ATMP Sweden – the national network of Sweden’s activities within Advanced Therapy Medicinal Products (ATMPs)

We need your input about prioritised ATMP topics and skill sets!

A short update on the Swedish ATMP association “Föreningen ATMP Sweden”

Preventing heart failure with extracellular vesicles and purified mitochondria

Lund Stem Cell Center ATMP mapping report launched

Save the date September 4-6 2024!

Join the 27th of June to discuss potential impact of recent EU legislation changes

CCRM Nordic AB to utilise 160 million SEK over 2 years to develop ATMP Innovation Cluster

Brought to you by ATMP Sweden – the national network of Sweden’s activities within Advanced Therapy Medicinal Products (ATMPs)

ATTRv patients, including Skelleftesjukan, receiving a ‘single shot’ towards a cure

National cluster to drive commercialisation, competence development and production

Join us to support the communication and coordination of Swedish ATMP

Tillväxtverket pilot study for hPSC derived cell therapies Innovation catalyst

Varför ska vi samverka mellan intressenter med olika kompetenser, erfarenheter och förutsättningar?

The Novo Nordisk/Karolinska Institutet/St Erik/Vecura model

Integrin a10b1 selected MSC in clinical development for Osteoarthritis and wound healing

Nyligen publicerats av Innovationsmiljön ATMP 2030 “Ökad kunskap och säkrad framtida kompetensförsörjning” arbetsgrupp

Register for ATMP 2030 launch, ATMP world tour and the CAMP + IndiCell hPSC-ATMP tour

The innovation milieu 'Sweden a world leader in advanced therapies 2030'

The national strategic project Swelife-ATMP has ended and the final report is now available

Ny rapport om Implementering av avancerade terapier och innovativa läkemedel i svensk hälso- och sjukvård

Closed symposia on the challenges in development of hPSC-ATMP and collaborative potential to drive the field forwards

Karolinska Institutet hosts Doug Melton on ZOOM January 11th 2022

Working towards improving outcomes of lung transplantations with PulmoStem

Matfors to be world leading in industrial ATMP manufacture

Press invitation: ATMP Sweden 2021

Enabling industrial scale production of mRNA and DNA based ATMPs and vaccines

Sweden’s BICO drives better and more accessible healthcare worldwide

Towards more industry engagement

Idogen's immune tolerance platform offers potential solutions to gene and cell therapies.

Robert Langer. Moderna founder, to present at ATMP Sweden 2021

MIT, Moderna and Bill Gates, leading the world in mRNA gene delivery medicines

An important step for patients with metastatic uveal melanoma.

Including launch of our ATMP Introductory course!

ATMP Sweden is about to get a new look

A Swedish precision medicine ATMP

Driving International dialogue in cell and gene therapy

Catch up on the latest including Swedish COVID-19 ATMPs and the ATMP world tour 2021!

Donors, manufacture, pharmacy and clinic….what permits are needed by who and from whom? What quality standards?

Tips for setting up MPA approved GMP manufacture facilities within a small cell therapy company

Catch up on the latest including launch of the commercialisation resources developed by Swelife-ATMP!

Find information and tools to assist in establishing your business model.

Develop your science, transverse skills and competencies to drive the next generation of ATMPs!

Together with KTH/AdBIOPRO and AstraZeneca, will explore scaleable magnetic-based cell separation

Where are we right now with Swedish ATMP manufacture, research and industry?

First foreign Company to join the Swedish ATMP network

Improved preservation of insulin production over 12 months in newly diagnosed adult type-1 diabetes patients

Three severly ill patients are now long term survivors in remission

Catch up on the latest including great results from our CAMP cell therapy project for Malignant Melanoma

Swelife-ATMP SDP4 releases their report on international competitiveness within Swedish gene therapy

48 million SEK partnership to develop pluripotent cell based cell therapy for Dry Macular Degeneration

Swelife-ATMP project SDP3 invitates comments and input on implications.

CellProtect Nordic Pharmaceuticals AB rebrands to XNK Therapeutics AB

Patients and their families are cautioned against using unproven cell based therapies.

Karolinska University Hospital and Karolinska Institutet become first Swedish CCC.

New Danaher operating company created following completion of $21.4B acquisition

Outlines and elaborating EuropaBio’s position and policy recommendations to the European Commission (EC)

CAMP HQ plasmid and pre-GMP projects pave way for Corona vaccine project

The latest on the 2020 conference and more

Interview with network coordinator Lilian Walther Jallow

"To keep up with the potential of this field we need to think and work innovatively, not competitively"

Sjöberg foundation awards 6 million over 3 years to engineering of T cells against Hepatocellular Carcinoma

Please spread this information to those with patients relevant to this trial.

Applications due 31st January, 2020.

Find ATMP relevant events in 2020 and links to sign up!

See our newsletter here and subscribe to receive directly!

Focus on precision medicine and ATMP

Vinnova awards 10 million SEK over two years to secure Sweden's ATMP future

Creates global cell and gene therapy manufacturing services platform

Promising results from Swedish study published in The New England Journal of Medicine

Two great courses covering some ATMP science and the field as a whole

Part 2 of our September 2019 ATMP financing events in Skåne.

Cobra Biologics invests 200 million SEK in Matfors facility

Genetically engineered bacteria to drive wound healing

Part one of our summary of ATMP financing events in Skåne September 2019

A centre for development of the next generation NK cell-based immunotherapies against cancer to be built from Karolinska Institutet.

Register for our finance events and AdBIOPRO bioreactor course

KARO1 is the first GMP hESC line produced at Vecura, there are more to come!

Real examples of taking ATMPs from research to market approval. Who do you need to be partnering with!?

Swedish gene therapy clinical trial for RLBP1 Retinitis Pigmentosa ongoing in Stockholm, Sweden

Sweden drives National and International collaboration to improve quality of life for burns survivors, saved through skin stem cell transplants

The Conference edition of our Newsletter! Read more about the success that was ATMP Sweden 2019!

The era of gene and cell therapy treatments is here!

Advanced therapies for future Healthcare

Good news from of one of our CAMP Projects "Expansion of GMP Compliant Tumor Infiltrating Lymphocytes (TILs) in Xuri bioreactor".

We are pleased to hear that Johan Hyllner has been recruited to AstraZeneca as Head of their Cell and Gene Therapy program.

VOG (tissue area Group) cell represents a National network of University hospitals in Sweden.

It's too cold to go outside, browse our newsletter instead!

Cobra is currently expanding capacity in both Keele, UK and Matfors, Sweden.

We caught up with Johan to see what his plans are post Catapult.

As part of CAMP WP1/WP2 Karolinska Institutet is setting up a pre-GMP core facility.

Welcome to the first CAMP/Swelife-ATMP quarterly ATMP newsletter!